Culture-Independent Analysis of Pediatric Bronchoalveolar Lavage Specimens

Philip Zachariah, Chanelle Ryan, Sruti Nadimpalli, Gina Coscia, Michelle Kolb, Hannah Smith, Marc Foca, Lisa Saiman, Paul J Planet, Philip Zachariah, Chanelle Ryan, Sruti Nadimpalli, Gina Coscia, Michelle Kolb, Hannah Smith, Marc Foca, Lisa Saiman, Paul J Planet

Abstract

Rationale: The clinical utility of culture-independent testing of pediatric BAL specimens is unknown. In addition, the variability of the pediatric pulmonary microbiome with patient characteristics is not well understood.

Objectives: To compare testing with 16S rRNA gene-based sequencing to conventional cultures of BAL specimens in children Methods: Study subjects were not more than 22 years old and underwent BAL from May 2013 to August 2015 as part of clinical care. DNA extracted from BAL specimens was used for 16S rRNA gene-based analysis, and results were compared with routine cultures from the same samples. Indices of microbial diversity and relative taxon abundances were compared on the basis of subject characteristics (diagnosis and antibiotic use).

Results: From 81 participants (male, 51%; median age, 9 yr), 89 samples were collected. The 16S rRNA genes of 77 samples (86.5%) from 70 subjects were successfully analyzed. These 70 subjects included 23 with cystic fibrosis, 19 who were immunocompromised, and 28 who were nonimmunocompromised. Of 68 organisms identified in culture, 16S rRNA gene-based analyses detected corresponding taxa in 66 (97.1%) and also identified potentially clinically significant organisms missed by cultures (e.g., Staphylococcus, Legionella, and Pseudomonas). Taxa that varied significantly with diagnosis and antibiotic use included Veillonella, Corynebacterium, Haemophilus, and Streptococcus. The microbiota of cystic fibrosis samples was less diverse. A "core" group of 15 taxa present in all three diagnosis groups was identified.

Conclusions: Culture-independent analysis was concordant with routine cultures and showed the potential to detect noncultured pathogens. Although culture-independent testing identified relative changes in organism abundance associated with clinical characteristics, distinct microbiome profiles associated with disease states were not identified.

Keywords: bronchoalveolar lavage; children; microbiome.

Figures

Figure 1.
Figure 1.
(A) Relative abundance, in operational taxonomic unit (OTU) read counts, of the most abundant taxon in each sample. The relative abundance of predominant cystic fibrosis (CF) OTUs was significantly higher than those of immunocompromised (IC) and nonimmunocompromised (nIC) samples following Kruskal-Wallis testing with Dunn’s multiple comparisons test. (B) Relative abundance of taxa that were isolated in the clinical laboratory. Solid points correspond to the most abundant taxa. Shaded points are nonpredominant taxa that were cultured. All samples were rarefied to 4,025 counts. **P = 0.0023, ****P < 0.0001.
Figure 2.
Figure 2.
(A) α diversity (Shannon-Weiner [SW]) within groups was compared using the Kruskal-Wallis test with Dunn’s multiple comparisons test. Cystic fibrosis (CF) samples were significantly less diverse than immunocompromised (IC) and nonimmunocompromised (nIC) samples. (B) Influence of concurrent treatment antibiotics on diversity (Shannon-Weiner) within diagnosis groups by two-way ANOVA with Tukey’s multiple comparisons test. CF samples, with and without treatment antibiotics, were less diverse than IC samples. CF samples without treatment antibiotics were also less diverse than nIC samples without antibiotics. There was no significant reduction in diversity within diagnosis groups due to concurrent treatment antibiotic use. Abx = antibiotics.*0.05 > P > 0.01, **0.01 > P > 0.001, ****P < 0.0001.
Figure 3.
Figure 3.
β diversity. Top: Dendrogram clustered by Bray-Curtis dissimilarity. Middle: Diagnosis class and concurrent antibiotic use of each sample. Bottom: Percent abundance of the top 10 most prevalent genera is shown in the corresponding stacked bar chart, with any remaining genera included in “other.” CF = cystic fibrosis; IC = immunocompromised; nIC = nonimmunocompromised.
Figure 4.
Figure 4.
Correlation of α diversity (Shannon-Weiner [SW]) with relative abundance of the most prevalent genera. Genera shown are significantly correlated with P values less than 0.0001. Corynebacterium (r = 0.37) and Haemophilus (r = 0.35) were also significantly correlated with P = 0.0011 and 0.0016, respectively. r = Pearson correlation statistic.
Figure 5.
Figure 5.
BAL core taxa identified as nonrandomly distributed. Taxa listed were present in at least 30% (gray) or at least 50% (bold) of samples. There are two [Prevotella] operational taxonomic units (OTUs) (belonging to the family Paraprevotellaceae) included in group A and two Stenotrophomonas OTUs in group E. CF = cystic fibrosis; IC = immunocompromised; nIC = nonimmunocompromised.

References

    1. Park JR, Fogarty S, Brogan TV. Clinical utility of bronchoalveolar lavage in pediatric cancer patients. Med Pediatr Oncol. 2002;39:175–180.
    1. Efrati O, Gonik U, Bielorai B, Modan-Moses D, Neumann Y, Szeinberg A, et al. Fiberoptic bronchoscopy and bronchoalveolar lavage for the evaluation of pulmonary disease in children with primary immunodeficiency and cancer. Pediatr Blood Cancer. 2007;48:324–329.
    1. Nadimpalli S, Foca M, Satwani P, Sulis ML, Constantinescu A, Saiman L. Diagnostic yield of bronchoalveolar lavage in immunocompromised children with malignant and non-malignant disorders. Pediatr Pulmonol. 2017;52:820–826.
    1. Srinivasan L, Pisapia JM, Shah SS, Halpern CH, Harris MC. Can broad-range 16S ribosomal ribonucleic acid gene polymerase chain reactions improve the diagnosis of bacterial meningitis? A systematic review and meta-analysis. Ann Emerg Med. 2012;60:609–620.e2.
    1. Vondracek M, Sartipy U, Aufwerber E, Julander I, Lindblom D, Westling K. 16S rDNA sequencing of valve tissue improves microbiological diagnosis in surgically treated patients with infective endocarditis. J Infect. 2011;62:472–478.
    1. Su G, Fu Z, Hu L, Wang Y, Zhao Z, Yang W. 16S ribosomal ribonucleic acid gene polymerase chain reaction in the diagnosis of bloodstream infections: a systematic review and meta-analysis. PLoS One. 2015;10:e0127195.
    1. Cui L, Morris A, Huang L, Beck JM, Twigg HL, III, von Mutius E, et al. The microbiome and the lung. Ann Am Thorac Soc. 2014;11:S227–S232.
    1. Pendleton KM, Erb-Downward JR, Bao Y, Branton WR, Falkowski NR, Newton DW, et al. Rapid pathogen identification in bacterial pneumonia using real-time metagenomics. Am J Respir Crit Care Med. 2017;196:1610–1612.
    1. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. J Clin Microbiol. 2014;52:3605–3613.
    1. Marsh RL, Kaestli M, Chang AB, Binks MJ, Pope CE, Hoffman LR, et al. The microbiota in bronchoalveolar lavage from young children with chronic lung disease includes taxa present in both the oropharynx and nasopharynx. Microbiome. 2016;4:37.
    1. Props R, Kerckhof FM, Rubbens P, De Vrieze J, Hernandez Sanabria E, Waegeman W, et al. Absolute quantification of microbial taxon abundances. ISME J. 2017;11:584–587.
    1. Boutin S, Graeber SY, Weitnauer M, Panitz J, Stahl M, Clausznitzer D, et al. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. PLoS One. 2015;10:e0116029.
    1. Laguna TA, Wagner BD, Williams CB, Stevens MJ, Robertson CE, Welchlin CW, et al. Airway microbiota in bronchoalveolar lavage fluid from clinically well infants with cystic fibrosis. PLoS One. 2016;11:e0167649.
    1. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6:1621–1624.
    1. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996–998.
    1. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336.
    1. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261–5267.
    1. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610–618.
    1. van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 2011;5:780–791.
    1. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med. 2013;7:245–257.
    1. Prevaes SM, de Winter-de Groot KM, Janssens HM, de Steenhuijsen Piters WA, Tramper-Stranders GA, Wyllie AL, et al. Development of the nasopharyngeal microbiota in infants with cystic fibrosis. Am J Respir Crit Care Med. 2016;193:504–515.
    1. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15:259–270.
    1. Frayman KB, Armstrong DS, Carzino R, Ferkol TW, Grimwood K, Storch GA, et al. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax. 2017;72:1104–1112.
    1. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One. 2012;7:e45001.
    1. Renwick J, McNally P, John B, DeSantis T, Linnane B, Murphy P Study of Host Immunity and Early Lung Disease in CF (SHIELD CF) The microbial community of the cystic fibrosis airway is disrupted in early life. PLoS One. 2014;9:e109798.
    1. Blainey PC, Milla CE, Cornfield DN, Quake SR. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. Sci Transl Med. 2012;4:153ra130.
    1. van der Gast CJ, Cuthbertson L, Rogers GB, Pope C, Marsh RL, Redding GJ, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc. 2014;11:1039–1048.
    1. Feigelman R, Kahlert CR, Baty F, Rassouli F, Kleiner RL, Kohler P, et al. Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details. Microbiome. 2017;5:20.
    1. Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, et al. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017;50:1700832.
    1. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, et al. Bacterial topography of the healthy human lower respiratory tract. MBio. 2017;8:e02287-16.
    1. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015;6:e00037.
    1. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184:957–963.
    1. Charlson ES, Bittinger K, Chen J, Diamond JM, Li H, Collman RG, et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS One. 2012;7:e42786.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe